Published in Semin Respir Crit Care Med on March 30, 2010
Respiratory viral infections in hematopoietic stem cell and solid organ transplant recipients. Semin Respir Crit Care Med (2011) 1.00
Central memory CD8+ T lymphocytes mediate lung allograft acceptance. J Clin Invest (2014) 0.99
Primary cytomegalovirus phosphoprotein 65-specific CD8+ T-cell responses and T-bet levels predict immune control during early chronic infection in lung transplant recipients. J Infect Dis (2011) 0.91
Long term complications following 54 consecutive lung transplants. J Thorac Dis (2016) 0.77
Lung Injury Combined with Loss of Regulatory T Cells Leads to De Novo Lung-Restricted Autoimmunity. J Immunol (2016) 0.75
Immune Responses to Tissue-Restricted Nonmajor Histocompatibility Complex Antigens in Allograft Rejection. J Immunol Res (2017) 0.75
Prevention of airway allograft tolerance by polyinosinic:polycytidylic acid requires type I interferon responsiveness for mouse airway obliteration. J Heart Lung Transplant (2013) 0.75
Hyperexpansion of Functional Viral-Specific CD8+ T Cells in Lymphopenia-Associated MCMV Pneumonitis. Viral Immunol (2015) 0.75
Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol (2000) 7.78
Infection in organ-transplant recipients. N Engl J Med (1998) 6.49
Rapid-test sensitivity for novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med (2009) 5.98
Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clin Infect Dis (2006) 5.71
Lung pathology in fatal novel human influenza A (H1N1) infection. Am J Respir Crit Care Med (2009) 4.37
Effector T cells control lung inflammation during acute influenza virus infection by producing IL-10. Nat Med (2009) 4.22
Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell (1997) 3.99
Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis (2004) 3.78
Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients - Seattle, Washington, 2009. MMWR Morb Mortal Wkly Rep (2009) 3.43
Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet (2000) 3.22
Functional heterogeneity and high frequencies of cytomegalovirus-specific CD8(+) T lymphocytes in healthy seropositive donors. J Virol (2000) 3.18
Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med (2008) 3.17
Activation of airway epithelial cells by toll-like receptor agonists. Am J Respir Cell Mol Biol (2004) 3.16
Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood (2002) 2.88
Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease. Blood (2002) 2.83
IL-10 deficiency unleashes an influenza-specific Th17 response and enhances survival against high-dose challenge. J Immunol (2009) 2.74
Cutting Edge: Influenza A virus activates TLR3-dependent inflammatory and RIG-I-dependent antiviral responses in human lung epithelial cells. J Immunol (2007) 2.73
A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. International Society for Heart and Lung Transplantation. J Heart Lung Transplant (1993) 2.69
Interlaboratory comparison of cytomegalovirus viral load assays. Am J Transplant (2009) 2.57
Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult lung and heart-lung transplantation report-2007. J Heart Lung Transplant (2007) 2.55
Registry of the International Society for Heart and Lung Transplantation: twenty-fifth official adult lung and heart/lung transplantation report--2008. J Heart Lung Transplant (2008) 2.15
Lungs are a major organ site of cytomegalovirus latency and recurrence. J Virol (1993) 2.04
Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult heart transplant report--2007. J Heart Lung Transplant (2007) 2.03
Systematic review: safety and efficacy of extended-duration antiviral chemoprophylaxis against pandemic and seasonal influenza. Ann Intern Med (2009) 1.99
Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death. Am J Respir Crit Care Med (2004) 1.95
Diagnosis of respiratory syncytial virus infection: comparison of reverse transcription-PCR to viral culture and serology in adults with respiratory illness. J Clin Microbiol (2002) 1.92
High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis (2001) 1.85
Influenza pneumonia in lung transplant recipients: clinical features and association with bronchiolitis obliterans syndrome. Chest (2001) 1.74
Human cytomegalovirus load in plasma and bronchoalveolar lavage fluid: a longitudinal study of lung transplant recipients. J Infect Dis (2004) 1.68
Interleukin 12 p40 production by barrier epithelial cells during airway inflammation. J Exp Med (2001) 1.68
Virus-induced abrogation of transplantation tolerance induced by donor-specific transfusion and anti-CD154 antibody. J Virol (2000) 1.64
Respiratory viral infection in obliterative airway disease after orthotopic tracheal transplantation. Ann Thorac Surg (2006) 1.63
CD8 T cells inhibit respiratory syncytial virus (RSV) vaccine-enhanced disease. J Immunol (2007) 1.57
Influenza virus infection in adult solid organ transplant recipients. Am J Transplant (2002) 1.52
Evaluation of CMV viral load using TaqMan CMV quantitative PCR and comparison with CMV antigenemia in heart and lung transplant recipients. Transplantation (2001) 1.44
Community respiratory virus infections in immunocompromised patients: hematopoietic stem cell and solid organ transplant recipients, and individuals with human immunodeficiency virus infection. Semin Respir Crit Care Med (2007) 1.42
Lower respiratory viral illnesses: improved diagnosis by molecular methods and clinical impact. Am J Respir Crit Care Med (2004) 1.40
Comparison of PCR, antigenemia assay, and rapid blood culture for detection and prevention of cytomegalovirus disease after lung transplantation. J Clin Microbiol (2000) 1.39
Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease. Immunol Res (2007) 1.33
Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant (2005) 1.22
New strategies for control of respiratory syncytial virus infection. Curr Opin Infect Dis (2008) 1.20
Respiratory syncytial virus immunobiology and pathogenesis. Virology (2002) 1.20
The value of polymerase chain reaction for the diagnosis of viral respiratory tract infections in lung transplant recipients. J Clin Virol (2002) 1.19
Cytomegalovirus and lung transplantation. Am J Transplant (2004) 1.17
Differential CMV-specific CD8+ effector T cell responses in the lung allograft predominate over the blood during human primary infection. J Immunol (2008) 1.15
Immunology of viral respiratory tract infection in infancy. Paediatr Respir Rev (2003) 1.14
Cytomegalovirus serologic status and postoperative infection correlated with risk of developing chronic rejection after pulmonary transplantation. Transplantation (1991) 1.13
Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation. Transplantation (2006) 1.12
The humoral immune response to influenza vaccination in lung transplant patients. Eur Respir J (2001) 1.08
Altered levels of CC chemokines during pulmonary CMV predict BOS and mortality post-lung transplantation. Am J Transplant (2008) 1.08
EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: results of a two-arm prospective trial. Am J Transplant (2008) 1.08
Ribavirin therapy in bone marrow transplant recipients with viral respiratory tract infections. Bone Marrow Transplant (1997) 1.05
Ganciclovir/valganciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation. Clin Infect Dis (2008) 1.03
Prospective study of human betaherpesviruses after renal transplantation: association of human herpesvirus 7 and cytomegalovirus co-infection with cytomegalovirus disease and increased rejection. Transplantation (2000) 1.03
Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naïve lung transplant recipient. Am J Respir Crit Care Med (1996) 1.02
Sequelae of cytomegalovirus pulmonary infections in lung allograft recipients. Am Rev Respir Dis (1992) 1.01
Human metapneumovirus in lung transplant recipients and comparison to respiratory syncytial virus. Am J Respir Crit Care Med (2008) 1.00
A single-season prospective study of respiratory viral infections in lung transplant recipients. Eur Respir J (2006) 0.99
Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am J Transplant (2004) 0.99
Suppression of both ELIP1 and ELIP2 in Arabidopsis does not affect tolerance to photoinhibition and photooxidative stress. Plant Physiol (2006) 0.98
A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome. J Heart Lung Transplant (2007) 0.97
Outcome of influenza infection managed with oseltamivir in lung transplant recipients. J Heart Lung Transplant (2008) 0.95
Detection of human cytomegalovirus antigenaemia: a rapid diagnostic technique for predicting cytomegalovirus infection/pneumonitis in lung and heart transplant recipients. Thorax (1995) 0.93
Parainfluenza virus infection in adult lung transplant recipients: an emergent clinical syndrome with implications on allograft function. Am J Transplant (2003) 0.93
Intravenous ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after lung transplantation. J Heart Lung Transplant (2005) 0.91
Reactivation of viruses in solid organ transplant patients receiving cytomegalovirus prophylaxis. Transplantation (2006) 0.91
Preparation of DNA dry powder for non-viral gene delivery by spray-freeze drying: effect of protective agents (polyethyleneimine and sugars) on the stability of DNA. J Pharm Pharmacol (2004) 0.90
The novel 2009 H1N1 influenza virus pandemic: unique considerations for programs in cardiothoracic transplantation. J Heart Lung Transplant (2009) 0.90
Human metapneumovirus--an important new respiratory virus. N Engl J Med (2004) 0.89
Clinical utility of cytomegalovirus viral load in bronchoalveolar lavage in lung transplant recipients. Am J Transplant (2005) 0.89
Treated cytomegalovirus pneumonia is not associated with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med (2004) 0.89
Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation: a comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone. Transplantation (2001) 0.89
Influenza and parainfluenza respiratory viral infection requiring admission in adult lung transplant recipients. Transplantation (2002) 0.88
Efficacy of oral ribavirin in lung transplant patients with respiratory syncytial virus lower respiratory tract infection. J Heart Lung Transplant (2009) 0.88
Human herpesvirus 6 in bronchalveolar lavage fluid after lung transplantation: a risk factor for bronchiolitis obliterans syndrome? Am J Transplant (2005) 0.88
Expression of gamma-IFN mRNA in bronchoalveolar lavage fluid correlates with early acute allograft rejection in lung transplant recipients. Clin Transplant (1999) 0.88
The epidemiology of parainfluenza virus infection in lung transplant recipients. Clin Infect Dis (2001) 0.88
Persistent cytomegalovirus-specific memory responses in the lung allograft and blood following primary infection in lung transplant recipients. J Immunol (2006) 0.88
Clinical features and outcomes of paramyxoviral infection in lung transplant recipients treated with ribavirin. J Heart Lung Transplant (2003) 0.87
A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation. Am J Respir Crit Care Med (1994) 0.86
Cytomegalovirus prevention in high-risk lung transplant recipients: comparison of 3- vs 12-month valganciclovir therapy. J Heart Lung Transplant (2009) 0.86
Adoptive T-cell therapy of a lung transplanted patient with severe CMV disease and resistance to antiviral therapy. Am J Transplant (2009) 0.86
Infectious etiology of bronchiolitis obliterans: the respiratory viruses connection - myth or reality? Am J Transplant (2003) 0.86
Perspective on the host response to human metapneumovirus infection: what can we learn from respiratory syncytial virus infections? Microbes Infect (2005) 0.85
Treatment of respiratory syncytial virus infection in haemopoietic stem cell transplant recipients with aerosolized ribavirin and the humanized monoclonal antibody palivizumab: a single centre experience. Br J Haematol (2009) 0.85
Combination prophylaxis with ganciclovir and cytomegalovirus (CMV) immune globulin after lung transplantation: effective CMV prevention following daclizumab induction. Am J Transplant (2003) 0.85
Postlung transplant survival is equivalent regardless of cytomegalovirus match status. Ann Thorac Surg (2007) 0.84
Early diagnosis of cytomegalovirus pneumonitis in lung transplant patients. Arch Pathol Lab Med (1995) 0.84
Cytomegalovirus DNA load patterns developing after lung transplantation are significantly correlated with long-term patient survival. Transplantation (2009) 0.83
The genetic archaeology of influenza. N Engl J Med (2004) 0.82
Preemptive therapy for systemic and pulmonary human cytomegalovirus infection in lung transplant recipients. Am J Transplant (2009) 0.82
CD8+ T-cell maturation following lung transplantation: the differential impact of CMV and acute rejection. Transpl Immunol (2007) 0.82
Evaluation of centrifugation cultures of bronchoalveolar lavage fluid for the diagnosis of cytomegalovirus pneumonitis. Diagn Microbiol Infect Dis (1988) 0.82
Respiratory viral infections aggravate airway damage caused by chronic rejection in rat lung allografts. Transplantation (1994) 0.81
Fever, human herpesvirus-6 (HHV-6) seroconversion, and acute rejection episodes as a function of the initial seroprevalence for HHV-6 in renal transplant recipients. Transplant Proc (2006) 0.81
Generation of HCMV-specific T-cell lines from seropositive solid-organ-transplant recipients for adoptive T-cell therapy. J Immunother (2009) 0.80
A multi-drug regimen for respiratory syncytial virus and parainfluenza virus infections in adult lung and heart-lung transplant recipients. Transpl Infect Dis (2009) 0.80
CD4+CD25+Foxp3+ Tregs resolve experimental lung injury in mice and are present in humans with acute lung injury. J Clin Invest (2009) 2.96
Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. Am J Respir Crit Care Med (2003) 2.80
Cytomegalovirus infection and the risk of mortality and frailty in older women: a prospective observational cohort study. Am J Epidemiol (2010) 1.85
Constitutive and inducible expression of b7 family of ligands by human airway epithelial cells. Am J Respir Cell Mol Biol (2005) 1.56
T cell responses to mycobacterial catalase-peroxidase profile a pathogenic antigen in systemic sarcoidosis. J Immunol (2008) 1.52
Activation-induced cell death drives profound lung CD4(+) T-cell depletion in HIV-associated chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2014) 1.50
F-box protein FBXL2 targets cyclin D2 for ubiquitination and degradation to inhibit leukemic cell proliferation. Blood (2012) 1.16
Association between obstructive lung disease and markers of HIV infection in a high-risk cohort. Thorax (2011) 1.16
Differential CMV-specific CD8+ effector T cell responses in the lung allograft predominate over the blood during human primary infection. J Immunol (2008) 1.15
Cross sectional analysis of respiratory symptoms in an injection drug user cohort: the impact of obstructive lung disease and HIV. BMC Pulm Med (2010) 1.06
Primary cytomegalovirus phosphoprotein 65-specific CD8+ T-cell responses and T-bet levels predict immune control during early chronic infection in lung transplant recipients. J Infect Dis (2011) 0.91
Pluripotent allospecific CD8+ effector T cells traffic to lung in murine obliterative airway disease. Am J Respir Cell Mol Biol (2005) 0.89
Persistent cytomegalovirus-specific memory responses in the lung allograft and blood following primary infection in lung transplant recipients. J Immunol (2006) 0.88
CD8(+)IL-17(+) T Cells Mediate Neutrophilic Airway Obliteration in T-bet-Deficient Mouse Lung Allograft Recipients. Am J Respir Cell Mol Biol (2015) 0.78
Pentraxin 3 in primary graft dysfunction: the long and short of it. Am J Respir Crit Care Med (2012) 0.75
Prevention of airway allograft tolerance by polyinosinic:polycytidylic acid requires type I interferon responsiveness for mouse airway obliteration. J Heart Lung Transplant (2013) 0.75
Infections in the immunosuppressed host. Ann Am Thorac Soc (2014) 0.75
Maintenance Belatacept-Based Immunosuppression in Lung Transplantation Recipients Who Failed Calcineurin Inhibitors. Transplantation (2017) 0.75
Models of Lung Transplant Research: a consensus statement from the National Heart, Lung, and Blood Institute workshop. JCI Insight (2017) 0.75
Induction of MHC-mismatched Mouse Lung Allograft Acceptance with Combined Donor Bone Marrow: Lung Transplant using a 12-Hour Nonmyeloablative Conditioning Regimen. Transplantation (2016) 0.75